Directorate Change

RNS Number : 2952Q

Epistem Holdings plc

11 October 2013

 

Re Directorate

("Epistem" or "the Company")

Further to its announcement on 1 August 2013, the Company today confirms that as of 10 October 2013 Jeff Moore resigned as a Director of Epistem and has now left the Company. The Company wishes Jeff Moore success as he pursues his other activities.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer                                 ++44 161 606 7258 

John Rylands, Chief Financial Officer

Peel Hunt LLP

Nominated Adviser: James Steel/Vijay Barathan                              ++44 207 418 8900  

Walbrook

Mike Wort/Anna Dunphy                                                                               ++44 207 933 8780

Notes to Editors:

About Epistem

Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.

Epistem develops novel therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.

 

END

 

 

BOAGGGPCUUPWUMG